JW HOLDINGS CORPORATION
A holding company under the JW Pharmaceutical group that directly handles overseas trade of pharmaceuticals such as carbapenems and nutritional solutions.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded and listed on KOSPI in 2007, JW Holdings is an operating holding company of the JW Pharmaceutical group. It directly handles overseas trade of raw materials, finished pharmaceuticals, and medical devices produced by its subsidiaries and sub-subsidiaries, including carbapenem antibiotics and nutritional solutions, while also earning revenue from equity income and brand royalties. In 2025, operating revenue fell 6.3% year-on-year to KRW 93.3 billion, with segment revenue split between holding operations at 45.2% and pharmaceutical trade at 54.8%; key items were nutritional solutions at KRW 24.1 billion, carbapenems at KRW 11.6 billion, and itraconazole at KRW 2.2 billion.
Products & technology
- Carbapenem antibioticsAntibiotic
- Nutritional solutionsIntravenous fluid
- ItraconazoleAntifungal agent
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition